Chronic kidney disease (CKD) is a silent epidemic. In this high-stakes space, biotechnology companies focused on reversing or slowing CKD progression are racing for a breakthrough. Successful clinical trials are not only scientific wins, but the catalysts that can ignite sector-wide rallies. Especially when the weapon isn't another pill, but cell therapy — an approach that could redefine kidney care as we know it.
One such player that just jolted the market is ProKidney (PROK), a biotech making noise with bold science and even bolder stock moves. Once backed by SPAC king Chamath Palihapitiya, this overlooked biotech stock just pulled off a 515% surge thanks to impressive top-line data from its Phase 2 REGEN-007 trial. Its autologous cell therapy, rilparencel (REACT), significantly slowed kidney function decline.
